Get the Stockscreener App
58.82
1.31%
0.76
Enliven Therapeutics Inc stock is traded at $58.82, with a volume of 350.22K.
It is up +1.31% in the last 24 hours and up +13.71% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$58.06
Open:
$57.67
24h Volume:
350.22K
Relative Volume:
0.25
Market Cap:
$4.31B
Revenue:
-
Net Income/Loss:
$-98.78M
P/E Ratio:
-35.35
EPS:
-1.6638
Net Cash Flow:
$-65.60M
1W Performance:
-2.71%
1M Performance:
+13.71%
6M Performance:
+120.13%
1Y Performance:
+197.52%
1-Day Range:
$56.69
$58.90
1-Week Range:
$56.69
$60.99
52-Week Range:
$14.79
$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
58.82 | 4.24B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN - MarketBeat
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026. - marketscreener.com
How (ELVN) Movements Inform Risk Allocation Models - Stock Traders Daily
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Lowered by Wall Street Zen - MarketBeat
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Enliven Therapeutics director Mika Derynck sells $9.56m shares By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Enliven Therapeutics (ELVN) and Geron (GERN) - The Globe and Mail
Enliven Therapeutics director Mika Derynck sells $9.56m shares - Investing.com
Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 158,795 Shares of Stock - MarketBeat
Insider Sale: Director at $ELVN Sells 158,795 Shares - Moomoo
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82 - Moomoo
Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside - TradingView
Enliven Therapeutics director Mika K. Derynck sells USD 9.56 million in common shares - Bitget
Stifel Nicolaus Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - MarketBeat
FMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership - Stock Titan
Guggenheim lowers Enliven Therapeutics stock price target to $78 By Investing.com - Investing.com Canada
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
The Goldman Sachs Group Raises Enliven Therapeutics (NASDAQ:ELVN) Price Target to $80.00 - MarketBeat
ENLIVEN THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $69 FROM $59 - Bitget
Enliven Therapeutics, Inc. 2Q 2026: Net loss $32.5M, EPS $(0.49) — 10-Q Summary - TradingView
ELVN: Strong Phase 1 results and FDA alignment set up ENABLE-2 trial, with $895M cash runway into 2030 - TradingView
ELVN: Net loss widened on higher R&D costs; strong cash reserves support pivotal ELVN-001 trial - TradingView
Enliven Therapeutics (NASDAQ: ELVN) raises $460M, ends Q2 with $895M cash - Stock Titan
Enliven Therapeutics reports Q2 net loss $32.5M; cash position $895.2M, plans Phase 3 for ELVN-001 - TradingView
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - marketscreener.com
ENLIVEN THERAPEUTICS, INC. : GUGGENHEIM CUTS TARGET PRICE TO $78 FROM $80 - Bitget
Enliven Therapeutics (NASDAQ:ELVN) Posts Earnings Results, Misses Expectations By $0.10 EPS - MarketBeat
Enliven Therapeutics (NASDAQ: ELVN) details planned stock sales via Jefferies - Stock Titan
Enliven Therapeutics stock hits 52-week high at $55.87 - Investing.com
Enliven Therapeutics stock hits 52-week high at $55.87 By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week HighWhat's Next? - MarketBeat
95,253 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by DV Trading LLC - MarketBeat
Enliven Therapeutics, Inc. (ELVN): Investor Outlook Highlights 23.98% Potential Upside - directorstalkinterviews.com
Stempoint Capital LP Makes New $14.25 Million Investment in Enliven Therapeutics, Inc. $ELVN - MarketBeat
ADAR1 Capital Management LLC Has $12.92 Million Holdings in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 6,018 Shares of Stock - MarketBeat
Enliven Therapeutics Inc (ELVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enliven Therapeutics Inc (ELVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ELVN|Enliven Therapeutics Inc|Price:52.750|Chg%:-0.200 - TradingKey
Enliven Therapeutics stock hits 52-week high at 54.9 USD - Investing.com
Enliven Therapeutics Inc (ELVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enliven Therapeutics stock hits 52-week high at 54.9 USD By Investing.com - Investing.com Canada
Enliven Therapeutics Inc (ELVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enliven Therapeutics Inc (ELVN) Cash Flow - TradingKey
Enliven Therapeutics Inc (ELVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):